Luc De Waal

Title: Luc De Waal: Innovator in Cancer Treatment

Introduction

Luc De Waal is a prominent inventor based in Boston, MA, known for his significant contributions to cancer treatment through innovative research and development. With a total of three patents to his name, he has made strides in identifying biomarkers that correlate with drug sensitivity in cancer patients.

Latest Patents

His latest patents include "Compounds, compositions and methods for cancer patient stratification and cancer treatment." This invention features improved compounds and methods for identifying cancer patients using biomarkers such as PDE3A, SLFN12, and CREB3L1. These biomarkers help in stratifying patients for more effective treatment options. Another notable patent is "Compositions and methods for cancer expressing PDE3A or SLFN12," which focuses on identifying patients with various types of cancer, including melanoma and breast cancer, using the same biomarkers to enhance treatment efficacy.

Career Highlights

Luc De Waal has worked with leading organizations in the pharmaceutical and research sectors. He has been associated with Bayer Pharma Aktiengesellschaft and The Broad Institute, Inc., where he has contributed to groundbreaking research in cancer therapies.

Collaborations

Throughout his career, Luc has collaborated with notable professionals in the field, including Alex Burgin and Monica Schenone. These collaborations have further enriched his research and development efforts.

Conclusion

Luc De Waal's innovative work in cancer treatment exemplifies the impact of research and invention in improving patient outcomes. His patents and collaborations highlight his commitment to advancing medical science and providing better treatment options for cancer patients.